Cerus (CERS) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cerus Corporation Announces Third Quarter 2019 Results
October 30, 2019 4:03 PM EDTCONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2019.
Recent developments and highlights include:
FDA issued its final guidance document on strategies to mitigate the risk of bacterial contamination in transfused platelet components Total third quarter revenue of $22.8 million Quarterly product revenue of $18.0 million, a 17% increase compared to the prior year quarter Government contract revenue of $4.8 million Worldwide demand for INTERCEPT continued to increase; calculated number of treatable platelet doses... More